Evidence map›Paper›PMID 42209292›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.

Fan Pu, Axiao Tao, Pengxiang Qiu, Weishan Deng, Zijian Chen, Zheng Cao, Yunjiao He, Peng George Wang, Yan Zhang, Chengqing Ning and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fan PuDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Axiao TaoDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Pengxiang QiuSchool of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Weishan DengDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Zijian ChenDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Zheng CaoDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Yunjiao HeSchool of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Peng George WangSchool of Medicine, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Yan ZhangDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Chengqing NingDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.
Xuechen LiDepartment of Chemistry, The University of Hong Kong, Hong Kong, People's Republic of China.
Jing XuDepartment of Chemistry and Shenzhen Grubbs Institute and Guangdong Provincial Key Laboratory of Catalysis and Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CDK7 has emerged as a highly promising anticancer target, as its dual indispensable roles in cell cycle progression and transcriptional regulation for cancer cell proliferation and survival. Herein, we describe the rational design and identification of novel tetracyclic CDK7 inhibitors with an azaindole/indole-fused pyrimidine scaffold, achieved via a cyclisation-based conformational restriction strategy. Compound

Indexed as

Antineoplastic AgentsAza CompoundsCyclin-Dependent KinasesDrug DiscoveryIndolesProtein Kinase InhibitorsPyrimidinesAnimalsCell ProliferationCyclin-Dependent Kinase-Activating KinaseDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMolecular StructureNeoplasms, ExperimentalAntineoplastic AgentsAza CompoundsCDK7 protein, humanCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesindoleIndolesProtein Kinase InhibitorspyrimidinePyrimidinesCDK7CDK7 inhibitorsConformational restrictionring closuretetracyclic scaffold

Identifiers

PMID42209292
PMCPMC13220591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.